Income StatementBalance SheetCash FlowSegments
Eli Lilly logo

Eli Lilly Business Segments

Business, geographic, and product segment breakdowns

Eli Lilly generates $72.2B in annual revenue across 4 key segments: Jardiance ($3.5B), Mounjaro ($27.8B), Neuroscience ($1.5B), and Other cardiometabolic health ($4.0B). Based on the Q1 2026 filing.

Jardiance (TTM)$3.5BMounjaro (TTM)$27.8BNeuroscience (TTM)$1.5BOther cardiometabolic health (TTM)$4.0BOther immunology (TTM)$1.8BOther oncology (TTM)$3.8BTaltz (TTM)$3.5BTrulicity (TTM)$4.1B
Latest FilingQ1 2026
Report Date2026-04-30
Market Cap$949.70B
P/E Ratio37.57
ROE107.65%

Products & Services

Potential achievements

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Ebglyss$1.3B$1.3B$1.3B$1.3B$1.2B$1.2B
Boehringer Ingelheim—$610.0M—$410.0M—$660.0M

Revenue

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Mounjaro$3.5B$3.8B$5.2B$6.5B$7.4B$8.7B
Zepbound$1.9B$2.3B$3.4B$3.6B$4.3B$4.2B
Verzenio$1.6B$1.2B$1.5B$1.5B$1.6B$1.3B
Jardiance$1.2B$1.0B$690.0M$959.0M$768.6M$1.1B
Other oncology$997.0M$789.0M$924.3M$937.4M$1.0B$966.0M
Trulicity$1.3B$1.1B$1.1B$1.1B$1.0B$919.0M
Other cardiometabolic health$1.2B$945.0M$980.4M$1.1B$1.0B$905.0M
Taltz$951.6M$762.0M$847.6M$901.5M$1.1B$733.0M
Other immunology$339.4M$326.0M$408.0M$460.9M$489.0M$470.0M
Neuroscience$393.6M$272.0M$344.0M$315.7M$459.2M$382.0M

R&D

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Late-stage$2.0B$1.7B$2.2B$2.2B$2.3B$2.2B
Early-stage$1.0B$990.0M$1.2B$1.2B$1.5B$1.3B

Geographic

Revenue

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
U.S.$9.0B$8.5B$10.8B$11.3B$12.9B$12.1B
Outside U.S.$4.5B$4.2B$4.7B$6.3B$6.4B$7.7B
Europe$2.4B$2.4B$2.6B$3.5B$3.1B$3.6B
Rest of world$1.1B$997.0M$1.2B$1.7B$2.2B$2.8B
China$428.8M$451.0M$465.9M$560.4M$473.2M$693.0M
Japan$559.3M$402.0M$521.0M$554.7M$654.8M$571.0M

Non-Current Assets

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Ireland$3.2B———$4.3B—
UNITED STATES And PUERTO RICO$13.4B———$18.8B—

Number of class action petitions

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Israel——2.002.002.002.00

Long-Lived Assets

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Rest of world$2.2B———$3.5B—

Business Segments

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Revenue$13.5B$12.7B$15.6B$17.6B$19.3B$19.8B
Net Income$4.4B$2.8B$5.7B$5.6B$6.6B$7.4B
Cost of Sales$2.4B$2.2B$2.4B$3.0B$3.4B$3.6B
Marketing, selling, and administrative$2.4B$2.5B$2.8B$2.7B$3.1B$2.9B
Expenditures for long-lived assets$1.6B$1.5B$2.0B$2.3B$2.9B$2.4B
Other segment items$1.1B$971.0M$1.2B$2.1B$1.8B$1.8B
Acquired in-process research and development$188.8M$1.6B$153.8M$655.7M$528.8M$584.0M
Interest Expense$224.7M$244.0M$249.0M$179.6M—$332.0M